In an interview to ET, CEO Vinita Gupta said the company had already exited a few products filed from its Somerset facility in New Jersey and has identified 15-20 more products to exit. "We need to look at whether we can sell through the inventory, we need to make sure that we don't really have the residual burn of the idle (capacity) cost on the company."from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d7rMEVn
via IFTTT
0 comments:
Post a Comment